I

n a modest victory for Novartis, a Japanese court decided the drug maker and a former employee were not guilty of violating a law that bans fraudulent and exaggerated advertising claims in connection with a research paper about the Diovan heart drug. A Novartis spokesman confirmed the ruling.

The decision stems from an episode in 2014 when the company was accused of altering data in a study in order to make the drug appear better than rival medicines. The research was conducted by several Japanese universities, some of which determined results were falsified.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories